Phase 2 Trial of Lenvatinib + Pembrolizumab for Progressive Disease After PD-1/PD-L1 Immune Checkpoint Inhibitor in Metastatic Clear Cell Renal Cell Carcinoma: Results by Independent Imaging Review and Subgroup Analyses